干扰素联合苦参素抗乙型肝炎病毒疗效观察

目的:探讨干扰素联合苦参素治疗慢性乙型肝炎的抗病毒效果。方法:98例慢性乙肝患者,随机分为治疗组51例,对照组47例。治疗组采用α干扰素5MU/d,肌注,连用15d后改tiw,疗程6个月。同时加用苦参素注射液-600mg/d,3个月后改口服苦参素胶囊,200mg,tid,疗程共6个月。对照组单用干扰素,剂量疗程相同。疗程结束时,观察两组患者乙肝病毒标志和HBV载量。结果:干扰素联合苦参素治疗组和对照组HBeAg阴转率分别为54.9%(28/51)与34.0%(16/47),P<0.05;HBsAg阴转率分别为9.8%(5/51)与6.4%(3/47),P>0.05;HBV-DNA阴转率分别为58.8%(30/51)与40.4%(19/47),P>0.05。结论:干扰素联合苦参素具有较好的抑制病毒复制功效并可减轻药物副反应故可作为慢,,性乙肝治疗方案的参考。

Antiviral Effects on Treatment of Chronic Hepatitis B by Interferon Alpha Combined with Oxymatrine

Objective: To study the antiviral effect of combination of interferon alpha(IFN-? and oxymatrine in treating chronic hepatitis B. Methods: 98 patients with chronic hepatitis B were randomly allocated to oxymatrine with IFN-?treatment group)or IFN-?ontrol group). The therapeutic course for them was 6 months, and the changes of HBsAg, HBeAg and HBV-DNA were observed and compared. Results: After treatment, the negative conversion rate of HBeAg in treatment group was 54.9%(28/51), and that in control group was 34.0% (16/47), the difference was significant(P<0.05).The negative conversion rates of HBsAg(9.8%,5/51;6.4%,3/47) and HBV-DNA (58.8%,30/51;40.4%,19/47) were not significantly different between two groups(P>0.05). Conclusion: IFN-?combined with oxymatrine shows better effect in treating chronic hepatitis B than that in using IFN-? alo ne.